Johnson & Johnson beat analyst expectations ... Spravato, which is derived from ketamine, is not a new drug—it first came on the market in 2019. The spray was previously approved as a companion ...

A mid-stage trial of oral ketamine tablets has shown promising results in treatment-resistant depression (TRD), setting up a phase 3 programme and a possible challenge to Johnson & Johnson’s ...

The nasal variant of ketamine, esketamine, was developed by Johnson & Johnson Pharmaceuticals under the name brand Spravato; it’s the only type of ketamine approved by the FDA for treatment ...

Across Lancashire, recorded offences for possession and supply of ketamine rose by nearly 70% from 54 in 2023 to 91 in 2024. "What we have seen, probably within the last 12 months, is the upturn in ...

Ketamine has gained attention for its depression ... beating its benchmark by 218 percentage points (see more details here). Johnson & Johnson (NYSE:JNJ) develops, manufactures, and sells a ...